argenx registers Phase 2a empasiprubart trial in gMG; adimanebart PK study recruiting
argenx posted two new trial records this week, one testing empasiprubart in generalized myasthenia gravis and one studying adimanebart pharmacokinetics in healthy adults.
argenx registered two clinical trial records during the week of June 29, 2026.
- The trial investigates the effects of empasiprubart in participants with AChR-Ab seropositive generalized myasthenia gravis (gMG).1 The study is a Phase 2a, randomized, placebo-controlled design, enrolling an estimated 40 participants,1 and is part of a larger platform study. The study is listed as recruiting, with an actual start date of 2026-07-10.1
- This Phase 1, open-label, randomized study assesses the absolute bioavailability and evaluates the effect of body weight on the pharmacokinetics of adimanebart SC in healthy adult participants.2 The trial is recruiting an estimated 52 healthy volunteers,2 with an actual start date of 2026-06-12.2
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.